Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia

• Status: Unknown status
• Trial end date: 2020-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Nilotinib vs imatinib in patients with newly diagnosed CML-CP

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Imatinib Mesylate

Criteria

Inclusion Criteria:

• chronic phase CML not received treatment

• Pts with no heart disease

• Pts with no abnormal cholesterol level

Exclusion Criteria:

• Any pts treated before with diff. Treatment

• Pts. With past history of heart problems

• Pts. With abnormal cholesterol level